Impact of Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs with Appendicular Osteosarcoma following Amputation and Carboplatin Chemotherapy: A Multi-Institutional Study
London C, Gardner H, Mathie T, Stingle N, Portela R, Pennell M, Clifford C, Rosenberg M, Vail D, Williams L, Cronin K, Wilson-Robles H, Borgatti A, Henry C, Bailey D, Locke J, Northrup N, Crawford-Jakubiak M, Gill V, Klein M, Ruslander D, Thamm D, Phillips B, Post G. Impact of Toceranib/Piroxicam/Cyclophosphamide Maintenance Therapy on Outcome of Dogs with Appendicular Osteosarcoma following Amputation and Carboplatin Chemotherapy: A Multi-Institutional Study. PLOS ONE 2015, 10: e0124889. PMID: 25923466, PMCID: PMC4414350, DOI: 10.1371/journal.pone.0124889.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, MetronomicAmputation, SurgicalAnimalsBone NeoplasmsCarboplatinCyclophosphamideDiarrheaDisease-Free SurvivalDog DiseasesDogsDrug Therapy, CombinationFemaleIndolesKaplan-Meier EstimateMaleNeutropeniaOsteosarcomaPiroxicamProspective StudiesPyrrolesRegression AnalysisTreatment OutcomeConceptsDisease-free intervalMedian disease-free intervalCarboplatin chemotherapyMetastatic diseaseOverall survivalControl dogsMaintenance therapyAppendicular osteosarcomaMedical conditionsSurvival rateTherapy-associated adverse eventsGross metastatic diseaseMedian overall survivalOutcome of dogsProspective clinical trialsYear survival rateMulti-institutional studyPiroxicam therapyCyclophosphamide therapyAdverse eventsPatient demographicsSupportive careStudy entryMetronomic treatmentClinical trials